Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2026)

Perspective Therapeutics (CATX) has 3 years of Non-Current Deffered Revenue data on file, last reported at $26.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $26.6 million; the trailing twelve-month figure through Mar 2026 stood at $26.6 million (changed 0.0% YoY), and the FY2025 full-year result was $26.6 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $26.6 million in Q1 2026, from $26.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $26.6 million in Q1 2024 to a low of $26.6 million in Q1 2024.
• A 3-year average of $26.6 million and a median of $26.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Tracing CATX's Non-Current Deffered Revenue over 3 years: stood at $26.6 million in 2024, then changed by 0.0% to $26.6 million in 2025, then changed by 0.0% to $26.6 million in 2026.
• Business Quant data shows CATX's Non-Current Deffered Revenue at $26.6 million in Q1 2026, $26.6 million in Q4 2025, and $26.6 million in Q3 2025.